Pharmacogenomic Testing for <i>CYP2C19</i> Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?
Pharmacogenomic testing for CYP2C19 variants is more economically justified for laboratories that serve a population enriched with CYP2C19 LOF alleles, than populations exhibiting a lower allele frequency. Within a clinical laboratory offering testing, restricting testing to certain populations is not ethical.
Authors
- Guanmin Chen
- Cody M. Orahoske (ORCID: https://orcid.org/0000-0001-8427-8891)
- Alan H.B. Wu (ORCID: https://orcid.org/0000-0002-5610-2036)
- Kiang-Teck J. Yeo
- Jose Estabil
Institutions
- University of California, San Francisco (US)
- University of Chicago (US)
- Xerox (United States) (US)
- Cipher Gene (China) (CN)
Publication Details
- Journal
- The Journal of Applied Laboratory Medicine
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1093/jalm/jfaf041
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39